Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMGP.L Regulatory News (MGP)

  • There is currently no data for MGP

Further re Acquisition

9 Jan 2008 08:46

Mercury Group PLC09 January 2008 9 January 2008 Mercury Group Plc (the "Company") Further re: Acquisition of Smith Melzack Pepper Angliss Limited The Company announces that it has entered into a Settlement Agreement with thevendors of Smith Melzack Pepper Angliss Limited ("SMPA") ("the Vendors"), whichwas acquired by the Company on 28 February 2005. Under the terms of the original sale and purchase agreement, the Vendors wereentitled to receive, under certain circumstances, deferred consideration andfurther deferred consideration. In November 2006, the Company notified the Vendors of certain claims for breachof warranty relating to PAYE claims ("the PAYE Claim"). The Company and the Vendors have agreed that in settlement of the PAYE Claim andany other warranty claims whether now or in the future, certain of theentitlement of the Vendors to the deferred consideration and the furtherdeferred consideration shall be set-off against the PAYE Claim, and the finalamount of the deferred consideration and further deferred consideration is£182,000 to be satisfied as follows: (a) as to 50 per cent. of such sum by the issue and allotment to the Vendors of,in aggregate, 4,550,000 ordinary shares in the issued share capital of theCompany ("Deferred Consideration Shares"); and (b) as to the remaining 50 per cent. by the issue of £91,000 in nominal amountof convertible unsecured loan stock ("Loan Stock"). The Loan Stock is convertible into ordinary shares in the Company at any time upto the first anniversary of issue at the rate of 50 ordinary shares for every £1nominal of Loan Stock. If the Loan Stock is not converted by such time, it shallbe repaid on the first anniversary of issue, together with interest accrued. TheLoan Stock will carry interest of 1.5 per cent. over three month LIBOR payablequarterly in arrears. The number of Deferred Consideration Shares and the nominal amount of the LoanStock shall be increased in equal proportions if and to the extent that theamount paid by the Company in full and final settlement of the PAYE Claim isless than £110,560. Any further ordinary shares will be issued at a price of 2pper share and any Loan Stock will be issued at par. Ronnie Franks, Stuart Sandler, Clive Orman, Alan Kleinman, Paul Vernon-Smith andColin Povey, who are directors of the Company and/or SMPA, comprise the Vendors.Accordingly, the Settlement Agreement is classified as a related partytransaction under the AIM Rules. The independent directors consider, havingconsulted with John East & Partners Limited, that the terms of the transactionare fair and reasonable insofar as the shareholders of Mercury are concerned. Application will be made for 4,550,000 ordinary shares to be admitted to tradingon the AIM Market and dealings are expected to commence on 14 January 2008. Enquiries: Mercury Group Plc George Kynoch - Chairman 020 7343 4000 John East & Partners Limited David Worlidge 020 7628 2200 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th May 20213:27 pmRNSDirector/PDMR Shareholding
28th May 20212:43 pmRNSDirector/PDMR Shareholding
25th May 20217:00 amRNSPosting of Annual Report and Notice of AGM
11th May 20217:10 amRNSNon-Executive Director Change
11th May 20217:10 amRNSResults for the year ended 31 December 2020
20th Apr 20219:30 amRNSHolding(s) in Company
16th Apr 20219:47 amRNSHolding(s) in Company
29th Mar 202110:48 amRNSHolding(s) in Company
25th Mar 20218:05 amRNSCompletion of Acquisition & Director/PDMR Dealings
23rd Mar 20219:31 amRNSCorrection: Results of Fundraise and TVR
23rd Mar 20217:00 amRNSResults of Fundraise and Total Voting Rights
23rd Mar 20217:00 amRNSRe-release: Proposed acquisition of US-based RadMD
22nd Mar 20215:07 pmRNSProposed Fundraise to raise approximately £16m
22nd Mar 20215:07 pmRNSProposed acquisition of US-based RadMD
19th Mar 20217:00 amRNSMicrosoft Research’s Dr Junaid Bajwa joins as NED
22nd Feb 20217:00 amRNSMedica and Integral Diagnostics establish JV, MedX
11th Feb 202110:09 amRNSHolding(s) in Company
29th Jan 20219:02 amRNSHolding(s) in Company
26th Jan 20217:00 amRNSAppointment of Liberum as Joint Corporate Broker
21st Jan 20217:00 amRNSTrading Update
18th Jan 20217:00 amRNSDr. Robert Lavis appointed Group Medical Director
4th Dec 202011:57 amRNSDirector/PDMR Shareholding
2nd Dec 20209:31 amRNSDirector/PDMR Shareholding
1st Dec 20209:34 amRNSHolding(s) in Company
18th Nov 20204:41 pmRNSSecond Price Monitoring Extn
18th Nov 20204:36 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSDirector/PDMR Shareholding
11th Nov 202012:41 pmRNSHolding(s) in Company
10th Nov 20201:56 pmRNSHolding(s) in Company
6th Nov 20202:26 pmRNSHolding(s) in Company
5th Nov 20207:00 amRNSDirector/PDMR Shareholding
4th Nov 20207:00 amRNSMedica acquires Global Diagnostics Ireland
27th Oct 20209:20 amRNSHolding(s) in Company
22nd Oct 20209:41 amRNSHolding(s) in Company
16th Oct 202011:26 amRNSHolding(s) in Company
7th Oct 202012:34 pmRNSHolding(s) in Company
16th Sep 20201:07 pmRNSDeclaration of Dividend
14th Sep 20207:00 amRNSInterim results demonstrate resilient performance
9th Sep 202010:36 amRNSHolding(s) in Company
25th Aug 20204:41 pmRNSSecond Price Monitoring Extn
25th Aug 20204:36 pmRNSPrice Monitoring Extension
14th Aug 20209:56 amRNSHolding(s) in Company
21st Jul 202010:49 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading Update
11th Jun 20203:22 pmRNSDirector/PDMR Shareholding
1st Jun 20204:54 pmRNSIssue of Equity
28th May 202010:14 amRNSHolding(s) in Company
21st May 202012:55 pmRNSHolding(s) in Company
20th May 20204:25 pmRNSResult of AGM
20th May 20207:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.